Tags: Drug.
Sarizotan (EMD-128130) is a selective 5-HT1A receptor agonist and D2 receptor antagonist which has antipsychotic effects and has also shown efficacy in reducing dyskinesias resulting from long-term anti-Parkinsonian treatment with levodopa.In June 2006 the developer Merck KGaA announced that the development of sarizotan was discontinued after two sarizotan Phase III studies (PADDY I PADDY II) failed to meet the primary efficacy endpoint and neither the Phase II findings nor the results from preclinical studies could be confirmed.
